logo-loader
viewImmuPharma PLC

Immupharma PLC - Total Share Capital Notification

RNS Number : 0027Q
Immupharma PLC
16 June 2020
 

RNS | eCorporate                                                                                                                                              16 June 2020

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Total Share Capital Notification

 

 

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:

 

Situation as at 16 June 2020

 

 

 

1. Information to be provided for on the basis of Article 15, §1, al. 1

 

 

 

Total of share capital (nominal value)

:

£ 18,301,092

 

 

 

Total number of shares with existing voting rights (= denominator) - one vote per share

:

183,010,920

 

 

 

2. Additional information to be provided on the basis of Article 15, §1, al. 2

 

In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors"

 

 

 

 

 

Convertible Securities (in whole or in part) into ordinary shares.

The total conversion would result in an equal number of voting rights

:

13,086,619

 

 

 

Share options (in whole or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights.

 

:

15,703,942

In respect to the announcement on 30 March 2020: "Subscription to raise £1.5m"

 

 

 

 

 

Warrants over ordinary shares (in whole or in part)

The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights

:

915,205

 

 

 

Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019)

 

 

 

 

 

Share options (in whole  or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights

:

16,368,850

 

 

 

 

This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBXGDLGSBDGGU

Quick facts: ImmuPharma PLC

Price: 14

Market: AIM
Market Cap: £25.62 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman 'delighted' with first significant investment from...

ImmuPharma PLC's (LON:IMM) Tim McCarthy speaks to Proactive London's Andrew Scott following the news of new funding through two specialist US healthcare investors. Up to US$6.3mln is being invested into IMM from an issue of unsecured convertible securities and associated options to L1 Capital...

on 15/6/20